Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Apr 9;113(15):3435-42.
doi: 10.1182/blood-2008-07-169565. Epub 2008 Oct 27.

Thalidomide-dexamethasone Compared With Melphalan-Prednisolone in Elderly Patients With Multiple Myeloma

Affiliations
Randomized Controlled Trial

Thalidomide-dexamethasone Compared With Melphalan-Prednisolone in Elderly Patients With Multiple Myeloma

Heinz Ludwig et al. Blood. .

Abstract

We compared thalidomide-dexamethasone (TD) with melphalan-prednisolone (MP) in 289 elderly patients with multiple myeloma (MM). Patients received either thalidomide 200 mg plus dexamethasone 40 mg, days 1 to 4 and 15 to 18 on even cycles and days 1 to 4 on odd cycles, during a 28-day cycle or to melphalan 0.25 mg/kg and prednisolone 2 mg/kg orally on days 1 to 4 during a 28- to 42-day cycle. Patients achieving stable disease or better were randomly assigned to maintenance therapy with either thalidomide 100 mg daily and 3 MU interferon alpha-2b thrice weekly or to 3 MU interferon alpha-2b thrice weekly only. TD resulted in a higher proportion of complete and very good remissions (26% vs 13%; P= .006) and overall responses (68% vs 50%; P= .002) compared with MP. Time to progression (21.2 vs 29.1 months; P= .2), and progression-free survival was similar (16.7 vs 20.7 months; P= .1), but overall survival was significantly shorter in the TD group (41.5 vs 49.4 months; P= .024). Toxicity was higher with TD, particularly in patients older than 75 years with poor performance status. The study was registered at ClinicalTrials.gov as NCT00205751.

Comment in

Similar articles

See all similar articles

Cited by 45 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback